Sir Alasdair Muir Breckenridge

[vc_row][vc_column width=”1/4″]Professor Sir Alasdair Breckenridge
[/vc_column][vc_column width=”3/4″]

Professor Sir Alasdair Breckenridge, United Kingdom

Sir Alasdair has made a significant contribution to the discipline in terms of advancement of scientific knowledge and demonstrating the need for clinical pharmacology expertise in national and international healthcare decision-making.

Aside from Sir Alasdair’s extensive research achievements, his impact at the international level has been significant in the form of serving on Steering Committees of the World Health Organisation, leadership roles within IUPHAR (International Union of Basic and Clinical Pharmacology) and serving as an Assessor for the European Union. Sir Alastair continues to be very active on a number of editorial boards and advisory bodies. He continues to be active in the Society, supporting our ongoing project to recognise the value of clinical pharmacology to the NHS and speaking at our training session for specialty registrars at Pharmacology 2014. His outstanding achievements have been recognised with the award of a Knight Bachelor in 2004 for services to medicine.

[/vc_column][/vc_row]

[vc_row][vc_column]
[wm_tabs active=”1″ ]

[wm_item title=”Nomination Letter”]

Research and clinical career

Sir Alasdair’s career in medicine began in St. Andrews University, graduating in 1961 with a prize for best medical student. He undertook clinical pharmacology training in London prior to his move to Liverpool in 1974. He did extensive research on warfarin leading to the award of the Paul Martini Prize in Clinical Pharmacology in 1974 for outstanding achievements and the 1975 Goulstonian lectureship of the Royal College of Physicians.

On his move to Liverpool, he aimed to expand the research horizons of the discipline beyond the focus of the time (cardiovascular disease). He achieved this in establishing a unified department of pharmacology (basic and clinical) and producing a large number of important publications concerning the kinetics, metabolism, dynamics and drug interactions of oral contraceptive steroids. Under his direction, the department developed close links with the Liverpool School of Tropical Medicine and started work on drugs used for tropical diseases (in particular malaria) and later on, the treatment of HIV, gaining an international reputation in these fields too. Sir Alasdair was also instrumental in developing and mentoring new talent, which is evidenced by the continuing strength of the Department of Pharmacology in Liverpool (recently awarded a BPS prize for Putting UK Pharmacology on the Map).

National impact

Sir Alasdair joined the Committee on Safety of Medicines in 1984 and became chair in 1999 until 2003. This was an independent body that advised the UK Licensing Authority on the quality, efficacy and safety of medicines. Sir Alasdair then served as the chair of the Medicine and Healthcare products Regulatory Agency (MHRA) for the next ten years. MHRA is an executive agency of the UK Department of Health which is responsible for ensuring that medicines and medical devices are effective and safe. He has been closely involved with the management of the National Health Service (NHS) at unit, regional and national levels including chairing the North West Regional Executive from 1995-1999.

He has been instrumental in the management of research on a national level, in particular the Medical Research Council (MRC) serving on the Council for four years and as a member of the Higher Education Funding Council of England. In addition to this, Sir Alasdair has been an
active member of the British Pharmacological Society serving as Foreign Secretary and a member of Council. BPS awarded him the Lilly Prize for distinction in clinical pharmacology in 1993 and an Honorary Fellowship in 2002. This represents the most prestigious clinical pharmacology prize the Society awards, as well as the highest honour the Society bestows in the form of Honorary Fellowship.

International impact

Aside from Sir Alasdair’s extensive research achievements, his impact at the international level has been significant in the form of serving on Steering Committees of the World Health Organisation, leadership roles within IUPHAR (International Union of Basic and Clinical Pharmacology) and serving as an Assessor for the European Union.

Sir Alastair continues to be very active on a number of editorial boards and advisory bodies. He continues to be active in the Society, supporting our ongoing project to recognise the value of clinical pharmacology to the NHS and speaking at our training session for specialty registrars at Pharmacology 2014. His outstanding achievements have been recognised with the award of a Knight Bachelor in 2004 for services to medicine. We highly commend him to the EACPT for this prestigious award.

The nomination letter was signed by

  1. Professor Munir Pirmohamed VP – Clinical
  2. Professor David Webb President
  3. Professor Stephen Hill President-Elect

British Pharmacological Society
07 September 2016

view original nomination letter

[/wm_item]

[wm_item title=”Curriculum Vitae”]

Education
1948-1954 Bell Baxter School, Cupar, Fife, Scotland
1954-1961 University of St. Andrews
Degrees
1958 B.Sc. in Biochemistry. St Andrews
1961 MB. ChB(with honours) St. Andrews
1964 MRCP London
1969 M.Sc. (with honours) London
1973 MD (with honours) Dundee
1974 FRCP London
1988 FRCP Edinburgh
1991 FRSE Edinburgh
1999 F Med Sci
Honorary Degrees
2005 Doctor of Science , University of Keele
2006 Doctor of Laws, University of Dundee
2006 Doctor of Medicine University of St. Andrews
2009 Doctor of Medicine, University of Liverpool
Previous Appointments
1961 House physician then house surgeon, Dundee Royal Infirmary
1962 Assistant, Department of Medicine, University of St.Andrews
1963 Senior House Physician ,Royal Postgraduate Medical School, London (Professor J.P.Shillingford then Dr C. Pallis)
1965 Research Assistant, Department of Medicine, Royal Postgraduate Medical School, London (Professor Sir J. Mc Michael)
1966 Senior Registrar in Clinical Pharmacology, Royal Postgraduate Medical School, London (Professor C T Dollery)
1969 Lecturer in Clinical Pharmacology, Royal Postgraduate Medical School, London. Consultant Physician, Hammersmith Hospital, London
1974 Senior Lecturer in Clinical Pharmacology, Royal Postgraduate Medical School, London Consultant Physician, Hammersmith Hospital, London
1975 Professor of Clinical Pharmacology, University of Liverpool
2003 Chairman of the Medicines and Healthcare products Regulatory Agency
Honours and Distinctions
Undergraduate
1954 Harkness Scholar, University of St. Andrews
1958 Taylor Thompson Scholar, University of St. Andrews
1961 Captain W.A.Low memorial medal as best medical graduate of the year
Postgraduate
1974 Paul Martini Prize in clinical pharmacology
1975 Goulstonian Lecturer, Royal College of Physicians
1981 British Pharmacological Society. Visitor to Australia
1988 Poulsen Medal of the Norwegian Pharmacological Society
1993 Lilly Prize of the British Pharmacological Society
2000 Honorary Fellowshiop of the Faculty of Pharmaceutical Medicine
2002 Honorary Fellowship of the British Pharmacological Society
Visiting Professorships
1978 University of Chandigarh, India
1980 University of Pretoria, South Africa
1982 Rayne Visiting Professor, University of Western Australia
1985 Otago Savings Bank Visiting Professor, University of Otago, New Zealand
1988 University Sains Malaysia, Penang
Honorary Degrees – See above
Civil Honours
1995 Commander of the British Empire (CBE)
2004 Knight Bachelor
Membership of Committees
National
National Health Service
1976-1993 Chairman of Mersey Region research Committee
1992-1995 Director of R and D North West Region
1995-1999 Chairman of North West Regional Executive
1984-1999 Committee on Safety of Medicines member then Chairman, 1999-2003
1982-1992 Advisor in clinical pharmacology to Chief Medical Officer, DH
2012- Non Executive Director of University College London Hospital (UCLH)
UK Higher Education Funding Council
1995-2002 Chairman of Joint Medical Advisory Committee
1980-1989 Member of University Grants Committee Panel on Subjects Allied to Medicine
Royal College of Physicians
1983-1986 Member of Council
1992-1997 Member of Research Advisory Committee
British Pharmacological Society
1979-1982 Member of Council
1985-1991 Foreign Secretary
Medical Research Council
1992-1996 Member of Council
1987-1991 Physiological Systems and Disorders Board
1983-1992 Clinical Trials Committee
1994-2002 AIDS Coordinating Committee
2001-2010 Chairman, OPTIMA HIV Trials Steering Committee
2002-2010 Chairman, SPARTAK HIV Trials Steering Committee
2005-2011 Chairman DART and ARROW HIV Trials Steering Committees
International
European Union
1992-2000 Assessor to Biomed 1 and 2 programmes
1995-1997 Assessor to Traing Mobility for Research programmes
World Health Organisation
1987-1991 Steering Committee on chemotherapy of filariasis
1987-1993 Steering Group on chemotherapy of malaria
1991-1994 Steering Committee of Product Development Unit
International Union of Pharmacology
1981-1987 Councillor
1981-1987 Councillor of Section on Clinical Pharmacology
1981 Chairman Scientific Committee of First World Congress of Clinical Pharmacology
Institute of Medicine
2007 Committee on The Future of Drug Safety
2010 Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs
Government of Singapore
Chairman of Advisory Committee of Centre of Regulatory Excellence, National University of Singapore-Duke University
Membership of Editorial Boards
1995- Clinical Pharmacology and Therapeutics
1990- European Journal of Clinical Pharmacology
1985- Clinical Pharmacokinetics
1985- Drugs
1985-1998 Executive Editor of Pharmacology and Therapeutics
1982-1988 Chairman of Editorial Board of British Journal of Clinical Pharmacology

[/wm_item]
[wm_item title=”Publications”]

  1. Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, Salmonson T, Schneider CK, Rasi G. The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013 Dec;12(12):907-16. doi: 10.1038/nrd4129. Epub 2013 Nov 15. PubMed PMID: 24232377.
  2. Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med. 2013 Oct;10(10):e1001542. doi: 10.1371/journal.pmed.1001542. Epub 2013 Oct 29. PubMed PMID: 24204216; PubMed Central PMCID: PMC3812080.
  3. Liberti L, McAuslane N, Patel P, Breckenridge A, Eichler HG, Peterson R. Regulatory review: How do agencies ensure the quality of decision making? Clin Pharmacol Ther. 2013 Sep;94(3):305-8. doi: 10.1038/clpt.2013.127. PubMed PMID: 23963218.
  4. Breckenridge A, Eichler HG. Towards a prevention model of health care. Nat Rev Drug Discov. 2013 Aug;12(8):563-4. doi: 10.1038/nrd4077. PubMed PMID: 23903207.
  5. Psaty BM, Goodman SN, Breckenridge A. Advances in regulatory science at the Food and Drug Administration. JAMA. 2013 May 22;309(20):2103-4. doi: 10.1001/jama.2013.4503. PubMed PMID: 23695478.
  6. ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M, Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C, Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013 Apr 20;381(9875):1391-403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7. PubMed PMID: 23473847; PubMed Central PMCID: PMC3641608.
  7. Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, Goodall RL, Grosskurth H, Mugyenyi P, Hakim J, Gibb DM; DART Virology Group and Trial Team. A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria. PLoS One. 2013;8(2):e57580. doi: 10.1371/journal.pone.0057580. Epub 2013 Feb 21. PubMed PMID: 23437399; PubMed Central PMCID: PMC3578828.
  8. Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, Musoke P, Gibb DM; ARROW Trial Team. Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe. Pediatr Infect Dis J. 2013 Aug;32(8):856-62. doi: 10.1097/INF.0b013e31828c3991. PubMed PMID: 23407100.
  9. Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators. Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters. Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8. PubMed PMID: 23331949; PubMed Central PMCID: PMC3605130.
  10. SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039. PubMed PMID: 23323897.
  11. Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R; SPARTAC Trial Investigators. Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection. AIDS. 2013 Jan 28;27(3):313-23. doi: 10.1097/QAD.0b013e32835b8cf5. PubMed PMID: 23095315.
  12. Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, Katabira E, Gilks CF, Kityo C, Nahirya-Ntege P, Nathoo K, Gibb DM; DART and ARROW trial teams. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012 Dec;55(12):1707-18. doi: 10.1093/cid/cis797. Epub 2012 Sep 12. PubMed PMID: 22972859; PubMed Central PMCID: PMC3501336.
  13. Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31. PubMed PMID: 22952756; PubMed Central PMCID: PMC3432055.
  14. Lumpkin MM, Eichler HG, Breckenridge A, Hamburg MA, Lönngren T, Woods K. Advancing the science of medicines regulation: the role of the 21st-century medicines regulator. Clin Pharmacol Ther. 2012 Oct;92(4):486-93. doi: 10.1038/clpt.2012.146. Epub 2012 Sep 5. Review. PubMed PMID: 22948890.
  15. Emanuel M, Rawlins M, Duff G, Breckenridge A. Thalidomide and its sequelae. Lancet. 2012 Sep 1;380(9844):781-3. doi: 10.1016/S0140-6736(12)60468-1. PubMed PMID: 22939670.
  16. Hudson I, Breckenridge A. The challenges of orphan drugs and orphan diseases: real and imagined. Clin Pharmacol Ther. 2012 Aug;92(2):151-3. doi: 10.1038/clpt.2012.72. PubMed PMID: 22814659.
  17. Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19. PubMed PMID: 22814125.
  18. Breckenridge A, Mello M, Psaty BM. New horizons in pharmaceutical regulation. Nat Rev Drug Discov. 2012 Jun 29;11(7):501-2. doi: 10.1038/nrd3787. Review. PubMed PMID: 22743964.
  19. Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Munderi P, Kyomugisha H, Hakim J, Grosskurth H, Gilks CF, Walker AS, Musoke P; DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9(5):e1001217. doi: 10.1371/journal.pmed.1001217. Epub 2012 May 15. PubMed PMID: 22615543; PubMed Central PMCID: PMC3352861.
  20. Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R, Tezikyabbiri J, Naidoo-James B, Gibb D; ARROW Trial Team. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One. 2012;7(5):e36186. doi: 10.1371/journal.pone.0036186. Epub 2012 May 2. PubMed PMID: 22567139; PubMed Central PMCID: PMC3342167.
  21. Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA. 2012 Jun 20;307(23):2491-2. doi: 10.1001/jama.2012.5545. PubMed PMID: 22563032.
  22. Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24. PubMed PMID: 22545079; PubMed Central PMCID: PMC3335836.
  23. Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? A view from regulators. PLoS Med. 2012;9(4):e1001202. doi: 10.1371/journal.pmed.1001202. Epub 2012 Apr 10. PubMed PMID: 22505851; PubMed Central PMCID: PMC3323505.
  24. Kiwuwa-Muyingo S, Walker AS, Oja H, Levin J, Miiro G, Katabira E, Kityo C, Hakim J, Todd J; DART Trial Team. The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. Trop Med Int Health. 2012 May;17(5):584-94. doi: 10.1111/j.1365-3156.2012.02974.x. Epub 2012 Mar 30. PubMed PMID: 22463596.
  25. Breckenridge A. Development and delivery of clinical pharmacology in regulatory agencies. Br J Clin Pharmacol. 2012 Jun;73(6):866-9. doi: 10.1111/j.1365-2125.2012.04226.x. PubMed PMID: 22360651; PubMed Central PMCID: PMC3391509.
  26. Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators. Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection. AIDS. 2012 Apr 24;26(7):887-90. doi: 10.1097/QAD.0b013e328351e721. PubMed PMID: 22313951.
  27. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther. 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21. PubMed PMID: 22190066.
  28. Collier A, Ghosh S, Breckenridge A, Perry CG, Freel EM, Davidson DF. A phaeochromocytoma occurring in a patient with Parkinson’s disease on L-dopa therapy: a diagnostic challenge. Clin Endocrinol (Oxf). 2012 May;76(5):763-4. doi: 10.1111/j.1365-2265.2011.04266.x. PubMed PMID: 22044043.
  29. Prasad K, Breckenridge A. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives. Drug Discov Today. 2011 Oct;16(19-20):867-72. doi: 10.1016/j.drudis.2011.08.016. Epub 2011 Sep 6. Review. PubMed PMID: 21920454.
  30. Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, Ferrier A, Lutakome J, Gibb DM, Burger DM, Walker AS; ARROW Trial Team. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):392-8. doi: 10.1097/QAI.0b013e318235e560. PubMed PMID: 21926634.
  31. Breckenridge A. Regulatory divergence. Clin Trials. 2011 Aug;8(4):425-6; discussion 430-1. doi: 10.1177/1740774511410456. PubMed PMID: 21835859.
  32. Dunn DT, Goodall RL, Munderi P, Kityo C, Ranopa M, Bacheler L, Van Houtte M, Gilks C, Kaleebu P, Pillay D; DART Virology and Trial Team. Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring. Antimicrob Agents Chemother. 2011 Oct;55(10):4575-80. doi: 10.1128/AAC.00580-11. Epub 2011 Jul 18. PubMed PMID: 21768516; PubMed Central PMCID: PMC3187016.
  33. English S, Katzourakis A, Bonsall D, Flanagan P, Duda A, Fidler S, Weber J, McClure M; SPARTAC Trial Investigators, Phillips R, Frater J. Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants. Retrovirology. 2011 Jul 7;8:54. doi: 10.1186/1742-4690-8-54. PubMed PMID: 21736738; PubMed Central PMCID: PMC3161944.
  34. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011 Jul 1;10(7):495-506. doi: 10.1038/nrd3501. PubMed PMID: 21720406.
  35. Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A. European perspective on risk management and drug safety. Clin Pharmacol Ther. 2011 May;89(5):650-4. doi: 10.1038/clpt.2011.28. PubMed PMID: 21512526.
  36. Breckenridge A, Feldschreiber P, Gregor S, Raine J, Mulcahy LA. Evolution of regulatory frameworks. Nat Rev Drug Discov. 2011 Jan;10(1):3-4. doi: 10.1038/nrd3348. PubMed PMID: 21193854.
  37. Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, Mugyenyi P, Kekitiinwa A, Bwakura-Dangarembizi MF, Crawley J; ARROW Trial Team. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J. 2011 Jun;30(6):535-7. doi: 10.1097/INF.0b013e3182076864. PubMed PMID: 21164384.
  38. Fryer HR, Frater J, Duda A, Roberts MG; SPARTAC Trial Investigators, Phillips RE, McLean AR. Modelling the evolution and spread of HIV immune escape mutants. PLoS Pathog. 2010 Nov 18;6(11):e1001196. doi: 10.1371/journal.ppat.1001196. PubMed PMID: 21124991; PubMed Central PMCID: PMC2987822.
  39. Munderi P, Snowden WB, Walker AS, Kityo C, Mosteller M, Kabuye G, Thoofer NK, Ssali F, Gilks CF, Hughes AR; DART Trial Team. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop Med Int Health. 2011 Feb;16(2):200-4. doi: 10.1111/j.1365-3156.2010.02688.x. Epub 2010 Nov 23. PubMed PMID: 21091860.
  40. Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, Hakim J, Munderi P, Chirara M, Ndembi N, Goodall RL, Yirrell DL, Burke A, Gilks CF, Kaleebu P; DART Virology and Trial Team. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr. 2010 Oct;55(2):277-83. doi: 10.1097/QAI.0b013e3181ea0df8. PubMed PMID: 20686411.
  41. Breckenridge A. Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther. 2010 Aug;88(2):153-4. doi: 10.1038/clpt.2010.76. PubMed PMID: 20648030.
  42. Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF, Gibb DM, Khoo S; DART Trial Team. Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother. 2010 Jul;54(7):2965-73. doi: 10.1128/AAC.01198-09. Epub 2010 Apr 26. PubMed PMID: 20421406; PubMed Central PMCID: PMC2897274.
  43. Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugyenyi P, Gibb DM, Gilks CF; DART/NORA trial teams. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010 May;11(5):334-44. doi: 10.1111/j.1468-1293.2009.00786.x. Epub 2010 Feb 3. PubMed PMID: 20136661.
  44. Breckenridge A, Woods K, Walley T. Medicines regulation and health technology assessment. Clin Pharmacol Ther. 2010 Feb;87(2):152-4. doi: 10.1038/clpt.2009.261. PubMed PMID: 20107448.
  45. Liberti L, Breckenridge A, Eichler HG, Peterson R, McAuslane N, Walker S. Expediting patients’ access to medicines by improving the predictability of drug development and the regulatory approval process. Clin Pharmacol Ther. 2010 Jan;87(1):27-31. doi: 10.1038/clpt.2009.179. PubMed PMID: 20019699.
  46. DART Trial Team, Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, Fadhiru K, Namyalo M, Zalwango A, Generous L, Khauka P, Rutikarayo N, Nakahima W, Mugisha A, Todd J, Levin J, Muyingo S, Ruberantwari A, Kaleebu P, Yirrell D, Ndembi N, Lyagoba F, Hughes P, Aber M, Lara AM, Foster S, Amurwon J, Wakholi BN, Whitworth J, Wangati K, Amuron B, Kajungu D, Nakiyingi J, Omony W, Fadhiru K, Nsibambi D, Khauka P, Mugyenyi P, Kityo C, Ssali F, Tumukunde D, Otim T, Kabanda J, Musana H, Akao J, Kyomugisha H, Byamukama A, Sabiiti J, Komugyena J, Wavamunno P, Mukiibi S, Drasiku A, Byaruhanga R, Labeja O, Katundu P, Tugume S, Awio P, Namazzi A, Bakeinyaga GT, Katabira H, Abaine D, Tukamushaba J, Anywar W, Ojiambo W, Angweng E, Murungi S, Haguma W, Atwiine S, Kigozi J, Namale L, Mukose A, Mulindwa G, Atwiine D, Muhwezi A, Nimwesiga E, Barungi G, Takubwa J, Murungi S, Mwebesa D, Kagina G, Mulindwa M, Ahimbisibwe F, Mwesigwa P, Akuma S, Zawedde C, Nyiraguhirwa D, Tumusiime C, Bagaya L, Namara W, Kigozi J, Karungi J, Kankunda R, Enzama R, Latif A, Hakim J, Robertson V, Reid A, Chidziva E, Bulaya-Tembo R, Musoro G, Taziwa F, Chimbetete C, Chakonza L, Mawora A, Muvirimi C, Tinago G, Svovanapasis P, Simango M, Chirema O, Machingura J, Mutsai S, Phiri M, Bafana T, Chirara M, Muchabaiwa L, Muzambi M, Mutowo J, Chivhunga T, Chigwedere E, Pascoe M, Warambwa C, Zengeza E, Mapinge F, Makota S, Jamu A, Ngorima N, Chirairo H, Chitsungo S, Chimanzi J, Maweni C, Warara R, Matongo M, Mudzingwa S, Jangano M, Moyo K, Vere L, Mdege N, Machingura I, Katabira E, Ronald A, Kambungu A, Lutwama F, Mambule I, Nanfuka A, Walusimbi J, Nabankema E, Nalumenya R, Namuli T, Kulume R, Namata I, Nyachwo L, Florence A, Kusiima A, Lubwama E, Nairuba R, Oketta F, Buluma E, Waita R, Ojiambo H, Sadik F, Wanyama J, Nabongo P, Oyugi J, Sematala F, Muganzi A, Twijukye C, Byakwaga H, Ochai R, Muhweezi D, Coutinho A, Etukoit B, Gilks C, Boocock K, Puddephatt C, Grundy C, Bohannon J, Winogron D, Gibb DM, Burke A, Bray D, Babiker A, Walker AS, Wilkes H, Rauchenberger M, Sheehan S, Spencer-Drake C, Taylor K, Spyer M, Ferrier A, Naidoo B, Dunn D, Goodall R, Darbyshire JH, Peto L, Nanfuka R, Mufuka-Kapuya C, Kaleebu P, Pillay D, Robertson V, Yirrell D, Tugume S, Chirara M, Katundu P, Ndembi N, Lyagoba F, Dunn D, Goodall R, McCormick A, Lara AM, Foster S, Amurwon J, Wakholi BN, Kigozi J, Muchabaiwa L, Muzambi M, Weller I, Babiker A, Bahendeka S, Bassett M, Wapakhabulo AC, Darbyshire JH, Gazzard B, Gilks C, Grosskurth H, Hakim J, Latif A, Mapuchere C, Mugurungi O, Mugyenyi P, Burke C, Jones S, Newland C, Pearce G, Rahim S, Rooney J, Smith M, Snowden W, Steens JM, Breckenridge A, McLaren A, Hill C, Matenga J, Pozniak A, Serwadda D, Peto T, Palfreeman A, Borok M, Katabira E. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8. PubMed PMID: 20004464; PubMed Central PMCID: PMC2805723.
  47. Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. Erratum in: J Infect Dis. 2010 Apr 15;201(8):1278. Ndembi, Nicasie [corrected to Ndembi, Nicaise]. PubMed PMID: 19938977.
  48. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009 Oct 31;374(9700):1533-42. doi: 10.1016/S0140-6736(09)61258-7. Epub 2009 Sep 16. Review. PubMed PMID: 19765816.
  49. Wise L, Parkinson J, Raine J, Breckenridge A. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov. 2009 Oct;8(10):779-82. doi: 10.1038/nrd3002. Epub 2009 Sep 18. PubMed PMID: 19763106.
  50. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST; OPTIMA Team1. Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9. doi: 10.1097/QAI.0b013e3181a4f00d. PubMed PMID: 19430303.
  51. Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Jackson P, Maxwell SR, McInnes GT, Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Williams D, Woods KL. The UK’s NHS and pharma: need for more clinical pharmacologists. Lancet. 2009 Apr 11;373(9671):1251-2. doi: 10.1016/S0140-6736(09)60726-1. PubMed PMID: 19362673.
  52. Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M, McClure M, McLean AR, Fidler S, Weber J, Phillips RE, Frater AJ; SPARTAC Trial Investigators. HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol. 2009 Feb;83(3):1228-39. doi: 10.1128/JVI.01545-08. Epub 2008 Nov 19. PubMed PMID: 19019964; PubMed Central PMCID: PMC2620910.
  53. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov. 2008 Oct;7(10):818-26. doi: 10.1038/nrd2664. Epub 2008 Sep 12. Review. PubMed PMID: 18787530.
  54. Breckenridge A, Hudson I. How European regulators view foreign data in the approval process. Clin Pharmacol Ther. 2008 Sep;84(3):311-2. doi: 10.1038/clpt.2008.84. PubMed PMID: 18714321.
  55. Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, Levin J, Katabira E, Gilks C, Todd J; DART Trial Team. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):468-75. doi: 10.1097/QAI.0b013e31817dc3fd. PubMed PMID: 18614918.
  56. Walley T, Breckenridge A. Pharmacoeconomics comes of age? Clin Pharmacol Ther. 2008 Aug;84(2):279-80. doi: 10.1038/clpt.2008.122. Epub 2008 Jun 18. PubMed PMID: 18563057.
  57. Breckenridge A, Walley T. Risk sharing and payment by results. Clin Pharmacol Ther. 2008 May;83(5):666-7. doi: 10.1038/clpt.2008.15. PubMed PMID: 18288081.
  58. Breckenridge A, Walley T. Early access to new medicines. Clin Pharmacol Ther. 2008 Jul;84(1):23-5. doi: 10.1038/clpt.2008.19. Epub 2008 Feb 20. PubMed PMID: 18288079.
  59. Breckenridge A. Post-marketing strategies for medicines. Clin Pharmacol Ther. 2008 Jan;83(1):24-5; discussion 25. Epub 2007 Nov 28. PubMed PMID: 18043682.
  60. Breckenridge A. The future of drug safety. Clin Pharmacol Ther. 2007 Feb;81(2):161-3. Review. PubMed PMID: 17259942.
  61. Breckenridge A. An audience with… Sir Alasdair Breckenridge. Interview by Joanna Owens. Nat Rev Drug Discov. 2006 Nov;5(11):888. PubMed PMID: 17117520.
  62. Breckenridge A. William Withering’s legacy–for the good of the patient. Clin Med. 2006 Jul-Aug;6(4):393-7. PubMed PMID: 16956147.
  63. Breckenridge A, Dollery C, Rawlins M, Walport M. The future of clinical pharmacology in the UK. Lancet. 2006 Apr 1;367(9516):1051. PubMed PMID: 16581393.
  64. Breckenridge A, Woods K. Medicines regulation and the pharmaceutical industry. BMJ. 2005 Oct 8;331(7520):834-6. Review. PubMed PMID: 16210285; PubMed Central PMCID: PMC1246088.
  65. Breckenridge A, Woods K, Raine J. Monitoring the safety of licensed medicines. Nat Rev Drug Discov. 2005 Jul;4(7):541-3. PubMed PMID: 15976815.
  66. Breckenridge A. The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium – December 2003. Br J Clin Pharmacol. 2004 Dec;58(6):571-4. PubMed PMID: 15563354; PubMed Central PMCID: PMC1884637.
  67. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet. 2004 Sep;5(9):676-80. Review. PubMed PMID: 15372090.
  68. Winstanley P, Ward S, Snow R, Breckenridge A. Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev. 2004 Jul;17(3):612-37, table of contents. Review. PubMed PMID: 15258096; PubMed Central PMCID: PMC452542.
  69. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15-9. PubMed PMID: 15231615; PubMed Central PMCID: PMC443443.
  70. Breckenridge A. Debate that “this house believes the essential drug concept hinders the effective deployment of drugs in developing countries”. Introduction. Trans R Soc Trop Med Hyg. 2003 Jan-Feb;97(1):1. PubMed PMID: 12886791.
  71. Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M. Reporting of adverse drug reactions by nurses. Lancet. 2003 Apr 19;361(9366):1347-8. PubMed PMID: 12711472.
  72. Breckenridge A. For the good of the patient: risks and benefits of medicines. Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):145-50. PubMed PMID: 12642978.
  73. Breckenridge A, Raine J. Concern about records of fibrosing colonopathy study. Lancet. 2001 May 12;357(9267):1527. PubMed PMID: 11386291.
  74. Pirmohamed M, Brown C, Owens L, Luke C, Gilmore IT, Breckenridge AM, Park BK. The burden of alcohol misuse on an inner-city general hospital. QJM. 2000 May;93(5):291-5. PubMed PMID: 10825405.
  75. Breckenridge A. Clinical pharmacology and drug regulation. Br J Clin Pharmacol. 1999 Jan;47(1):11-2. PubMed PMID: 10073733; PubMed Central PMCID: PMC2014199.
  76. Reidenberg MM, Breckenridge A. Drugs and the liver. Clin Pharmacol Ther. 1998 Oct;64(4):353-4. PubMed PMID: 9797790.
  77. Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS. 1998 Jul 9;12(10):1163-7. PubMed PMID: 9677165.
  78. Breckenridge AM, Winstanley PA. Clinical pharmacology and malaria. Ann Trop Med Parasitol. 1997 Oct;91(7):727-33. Review. PubMed PMID: 9625927.
  79. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ. 1998 Apr 25;316(7140):1295-8. Review. PubMed PMID: 9554902; PubMed Central PMCID: PMC1113033.
  80. Arlett PR, Lee EH, Hooker M, Darbyshire JH, Breckenridge AM. Reporting adverse drug reactions in HIV infection. Genitourin Med. 1997 Oct;73(5):335. PubMed PMID: 9534739; PubMed Central PMCID: PMC1195887.
  81. Rawlins MD, Breckenridge AM. Clinical benefit must not be confused with cost benefit. BMJ. 1998 Jan 24;316(7127):310-1. PubMed PMID: 9472543; PubMed Central PMCID: PMC2665476.
  82. Rawlins MD, Breckenridge AM, Wood SM, Waller PC, Coulson R. Adverse drug reaction of the month–a new series. Postgrad Med J. 1997 Jul;73(861):385. PubMed PMID: 9338019; PubMed Central PMCID: PMC2431412.
  83. Breckenridge A, Kitchen V, Darbyshire JH. Antiretroviral drug trials. Science. 1997 Jun 6;276(5318):1481-2; author reply 1443-4. PubMed PMID: 9190678.
  84. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, Back DJ. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 1997 Mar 15;11(4):F29-33. PubMed PMID: 9084785.
  85. Barry MG, Khoo SH, Veal GJ, Hoggard PG, Gibbons SE, Wilkins EG, Williams O, Breckenridge AM, Back DJ. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS. 1996 Oct;10(12):1361-7. PubMed PMID: 8902065.
  86. Breckenridge A. A clinical pharmacologist’s view of drug toxicity. Br J Clin Pharmacol. 1996 Jul;42(1):53-8. Review. PubMed PMID: 8807144; PubMed Central PMCID: PMC2042640.
  87. Pirmohamed M, Williams D, Tingle MD, Barry M, Khoo SH, O’Mahony C, Wilkins EG, Breckenridge AM, Park BK. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS. 1996 May;10(5):501-7. PubMed PMID: 8724041.
  88. Breckenridge A. Clinical pharmacology in the 1990s: a personal perspective. Mater Med Pol. 1995 Oct-Dec;27(4):135-6. PubMed PMID: 9000835.
  89. Barry MG, Back DJ, Breckenridge AM. Zidovudine therapy in HIV infection: which patients should be treated and when. Br J Clin Pharmacol. 1995 Aug;40(2):107-10. Review. PubMed PMID: 8562291; PubMed Central PMCID: PMC1365168.
  90. Breckenridge A. Science, medicine and clinical pharmacology. The Lilly Lecture 1994. Br J Clin Pharmacol. 1995 Jul;40(1):1-9. Review. PubMed PMID: 8527257; PubMed Central PMCID: PMC1365020.
  91. Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM, Watkins WM. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52. PubMed PMID: 7786001; PubMed Central PMCID: PMC162659.
  92. Breckenridge A. Clinical pharmacology and therapeutics. BMJ. 1995 Feb 11;310(6976):377-80. Review. PubMed PMID: 7866217; PubMed Central PMCID: PMC2548766.
  93. Ng HW, Walleyl TJ, Tsao Y, Fahal IH, Ahmad R, Breckenridge AM. Comparison of bioimpedance and Doppler ultrasound cardiac output in CAPD patients. Methods Find Exp Clin Pharmacol. 1995 Jan-Feb;17(1):59-65. PubMed PMID: 7623522.
  94. Breckenridge A. The Culyer report. Lancet. 1994 Dec 24-31;344(8939-8940):1775. PubMed PMID: 7997027.
  95. Barry M, Wild M, Veal G, Back D, Breckenridge A, Fox R, Beeching N, Nye F, Carey P, Timmins D. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS. 1994 Aug;8(8):F1-5. PubMed PMID: 7986398.
  96. Waller PC, Wood SM, Breckenridge AM, Rawlins MD. Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed. Br J Clin Pharmacol. 1994 Aug;38(2):93. PubMed PMID: 7981018; PubMed Central PMCID: PMC1364851.
  97. Barry M, Howe JL, Ormesher S, Back DJ, Breckenridge AM, Bergin C, Mulcahy F, Beeching N, Nye F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol. 1994 May;37(5):421-6. PubMed PMID: 8054247; PubMed Central PMCID: PMC1364896.
  98. Walley T, Bligh J, Orme M, Breckenridge A. Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future. Br J Clin Pharmacol. 1994 Feb;37(2):137-43. PubMed PMID: 8186060; PubMed Central PMCID: PMC1364590.
  99. Walley T, Bligh J, Orme M, Breckenridge A. Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status. Br J Clin Pharmacol. 1994 Feb;37(2):129-35. PubMed PMID: 8186059; PubMed Central PMCID: PMC1364589.
  100. Barry M, Howe JL, Back DJ, Swart AM, Breckenridge AM, Weller IV, Beeching N, Nye F. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol. 1994 Jan;37(1):7-12. PubMed PMID: 8148221; PubMed Central PMCID: PMC1364702.
  101. Ng HW, Walley TJ, Tsao Y, Breckenridge AM. Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects. Eur J Clin Pharmacol. 1994;46(4):361-5. PubMed PMID: 7957523.
  102. Barry M, Howe J, Back D, Breckenridge A, Brettle R, Mitchell R, Beeching NJ, Nye FJ. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. Br J Clin Pharmacol. 1993 Jul;36(1):82-5. PubMed PMID: 8373716; PubMed Central PMCID: PMC1364561.
  103. Breckenridge A. Clinical pharmacology in the 1990s: a personal perspective. Clin Investig. 1993 Jun;71(6):478-9. PubMed PMID: 8353408.
  104. Helsby NA, Edwards G, Breckenridge AM, Ward SA. The multiple dose pharmacokinetics of proguanil. Br J Clin Pharmacol. 1993 Jun;35(6):653-6. PubMed PMID: 8329294; PubMed Central PMCID: PMC1381611.
  105. Walley T, Tsao Y, Scott A, Mackay E, Vandenburg M, Breckenridge A. Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients. Br J Clin Pharmacol. 1993 Jun;35(6):623-8. PubMed PMID: 8329290; PubMed Central PMCID: PMC1381606.
  106. Kokwaro GO, Glazier AP, Ward SA, Breckenridge AM, Edwards G. Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes. Biochem Pharmacol. 1993 Mar 24;45(6):1235-41. PubMed PMID: 8466544.
  107. Pirmohamed M, Coleman MD, Galvani D, Bucknall RC, Breckenridge AM, Park BK. Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis. Br J Rheumatol. 1993 Mar;32(3):222-6. PubMed PMID: 8095423.
  108. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem Pharmacol. 1992 Dec 15;44(12):2307-14. PubMed PMID: 1472096.
  109. Ng HW, Coleman N, Walley TJ, Mostafa SM, Breckenridge AM. Reproducibility and comparison of cardiac output measurement by transthoracic bioimpedance and thermodilution methods in critically ill patients. Clin Intensive Care. 1993;4(5):217-21. PubMed PMID: 10146700.
  110. Wanwimolruk S, Edwards G, Ward SA, Breckenridge AM. The binding of the antimalarial arteether to human plasma proteins in-vitro. J Pharm Pharmacol. 1992 Nov;44(11):940-2. PubMed PMID: 1361544.
  111. Roberts DH, Tsao Y, Linge K, McLoughlin GA, Breckenridge A. Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology. 1992 Sep;43(9):748-56. PubMed PMID: 1514711.
  112. Coleman MD, Rhodes LE, Scott AK, Verbov JL, Friedmann PS, Breckenridge AM, Park BK. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol. 1992 Sep;34(3):244-9. PubMed PMID: 1389948; PubMed Central PMCID: PMC1381395.
  113. Waller PC, Wood SM, Langman MJ, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. BMJ. 1992 Jun 6;304(6840):1470-2. PubMed PMID: 1611368; PubMed Central PMCID: PMC1882252.
  114. Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol. 1992 Apr 15;43(8):1675-82. PubMed PMID: 1575766.
  115. Scott AK, Grimes S, Ng K, Critchley M, Breckenridge AM, Thomson C, Pilgrim AJ. Sumatriptan and cerebral perfusion in healthy volunteers. Br J Clin Pharmacol. 1992 Apr;33(4):401-4. PubMed PMID: 1315562; PubMed Central PMCID: PMC1381329.
  116. Edwards G, Ward S, Breckenridge A. Interaction of arteether with the red blood cell in-vitro and its possible importance in the interpretation of plasma concentrations in-vivo. J Pharm Pharmacol. 1992 Mar;44(3):280-1. Erratum in: J Pharm Pharmacol 1992 Apr;44(4):following 370. PubMed PMID: 1354744.
  117. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol. 1992 Feb;33(2):183-6. PubMed PMID: 1550698; PubMed Central PMCID: PMC1381305.
  118. Breckenridge A. Clinical significance of interactions with antifungal agents. Br J Dermatol. 1992 Feb;126 Suppl 39:19-22. Review. PubMed PMID: 1311944.
  119. Breckenridge A, Roberts D, Walley T. Different vasodilating mechanisms–different peripheral effects? J Cardiovasc Pharmacol. 1992;19 Suppl 1:S23-6. PubMed PMID: 1378145.
  120. Pirmohamed M, Graham A, Roberts P, Smith D, Chadwick D, Breckenridge AM, Park BK. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol. 1991 Dec;32(6):741-9. PubMed PMID: 1768568; PubMed Central PMCID: PMC1368556.
  121. Scott AK, Walley T, Breckenridge AM, Lacey LF, Fowler PA. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol. 1991 Nov;32(5):581-4. PubMed PMID: 1659437; PubMed Central PMCID: PMC1368634.
  122. Ng HW, Walley T, Tsao Y, Breckenridge AM. Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers. Br J Clin Pharmacol. 1991 Sep;32(3):275-82. PubMed PMID: 1777364; PubMed Central PMCID: PMC1368518.
  123. Pirmohamed M, Coleman MD, Hussain F, Breckenridge AM, Park BK. Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Br J Clin Pharmacol. 1991 Sep;32(3):303-10. PubMed PMID: 1685664; PubMed Central PMCID: PMC1368522.
  124. Mansor SM, Ward SA, Edwards G, Hoaksey PE, Breckenridge AM. The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. J Pharm Pharmacol. 1991 Sep;43(9):650-4. PubMed PMID: 1685525.
  125. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol. 1991 Jul;32(1):17-21. PubMed PMID: 1909542; PubMed Central PMCID: PMC1368487.
  126. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism–a panel study. Br J Clin Pharmacol. 1991 Jun;31(6):689-92. PubMed PMID: 1867963; PubMed Central PMCID: PMC1368581.
  127. Breckenridge A. Clinical Pharmacology in the United Kingdom–a view for the 1990s. Br J Clin Pharmacol. 1991 Mar;31(3):249-50. PubMed PMID: 2054262; PubMed Central PMCID: PMC1368347.
  128. Breckenridge A. Angiotensin converting enzyme inhibitors and quality of life. Am J Hypertens. 1991 Jan;4(1 Pt 2):79S-82S. Review. PubMed PMID: 2009155.
  129. Breckenridge A, Roberts DH. Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol. J Cardiovasc Pharmacol. 1991;18 Suppl 4:S78-81. Review. PubMed PMID: 1721985.
  130. Awadzi K, Schulz-Key H, Edwards G, Breckenridge A, Orme M, Gilles H. The chemotherapy of onchocerciasis. XIV. Studies with mebendazole citrate. Trop Med Parasitol. 1990 Dec;41(4):383-6. PubMed PMID: 2075382.
  131. Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol. 1990 Nov;30(5):761-7. PubMed PMID: 2271376; PubMed Central PMCID: PMC1368178.
  132. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol. 1990 Oct;30(4):593-8. PubMed PMID: 2291871; PubMed Central PMCID: PMC1368250.
  133. Helsby NA, Ward SA, Howells RE, Breckenridge AM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol. 1990 Aug;30(2):287-91. PubMed PMID: 2206791; PubMed Central PMCID: PMC1368230.
  134. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):492-5. PubMed PMID: 2091335.
  135. Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, Orme ML, Breckenridge AM. The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol. 1990 Jun;29(6):695-701. PubMed PMID: 2378788; PubMed Central PMCID: PMC1380171.
  136. Mansor SM, Ward SA, Edwards G, Hoaksey PE, Breckenridge AM. The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. J Pharm Pharmacol. 1990 Jun;42(6):428-32. PubMed PMID: 1979624.
  137. Bem JL, Wood SM, West L, Rawlins MD, Breckenridge AM. 25 years of the Committee on Safety of Medicines. An international perspective of the benefits. Drug Saf. 1990 May-Jun;5(3):161-7. PubMed PMID: 2350440.
  138. Coleman MD, Hoaksey PE, Breckenridge AM, Park BK. Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. J Pharm Pharmacol. 1990 May;42(5):302-7. PubMed PMID: 1976775.
  139. Winstanley PA, Coleman JW, Maggs JL, Breckenridge AM, Park BK. The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. Br J Clin Pharmacol. 1990 Apr;29(4):479-85. PubMed PMID: 2328196; PubMed Central PMCID: PMC1380119.
  140. Coleman MD, Winn MJ, Breckenridge AM, Park BK. Sex-dependent sensitivity to dapsone-induced methaemoglobinaemia in the rat. Biochem Pharmacol. 1990 Feb 15;39(4):805-9. PubMed PMID: 2306286.
  141. Coleman MD, Winn MJ, Breckenridge AM, Park BK. Inhibition of dapsone-induced methaemoglobinaemia in the rat. Biochem Pharmacol. 1990 Feb 15;39(4):802-5. PubMed PMID: 2306285.
  142. Walley T, Winstanley P, Roberts D, Grimmer M, Orme M, Breckenridge A. Adverse effects of captopril in hospital outpatients with hypertension. Postgrad Med J. 1990 Feb;66(772):106-9. PubMed PMID: 2190201; PubMed Central PMCID: PMC2429545.
  143. Karbwang J, Back DJ, Bunnag D, Breckenridge AM. Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria. Bull World Health Organ. 1990;68(5):633-8. PubMed PMID: 2289299; PubMed Central PMCID: PMC2393179.
  144. Orme M, Edwards G, Awadzi K, Breckenridge A. Clinical pharmacokinetics of drugs against onchocerciasis. Acta Leiden. 1990;59(1-2):329-42. Review. PubMed PMID: 2198757.
  145. Breckenridge A. Risks and benefits of prophylactic antimalarial drugs. BMJ. 1989 Oct 28;299(6707):1057-8. Review. PubMed PMID: 2511961; PubMed Central PMCID: PMC1837973.
  146. Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol. 1989 Oct;28(4):389-95. PubMed PMID: 2590600; PubMed Central PMCID: PMC1379987.
  147. Tjia JF, Back DJ, Breckenridge AM. Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes. Br J Clin Pharmacol. 1989 Sep;28(3):362-5. PubMed PMID: 2789931; PubMed Central PMCID: PMC1379957.
  148. Idowu OR, Edwards G, Ward SA, Orme ML, Breckenridge AM. Determination of arteether in blood plasma by high-performance liquid chromatography with ultraviolet detection after hydrolysis acid. J Chromatogr. 1989 Aug 25;493(1):125-36. PubMed PMID: 2778002.
  149. Milton KA, Edwards G, Ward SA, Orme ML, Breckenridge AM. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol. 1989 Jul;28(1):71-7. PubMed PMID: 2775616; PubMed Central PMCID: PMC1379972.
  150. Winstanley PA, Irvin LE, Smith JC, Orme ML, Breckenridge AM. Adverse drug reactions: a hospital pharmacy-based reporting scheme. Br J Clin Pharmacol. 1989 Jul;28(1):113-6. PubMed PMID: 2775609; PubMed Central PMCID: PMC1379978.
  151. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RE, Breckenridge AM. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol. 1989 Jun;27(6):781-7. PubMed PMID: 2757894; PubMed Central PMCID: PMC1379805.
  152. Breckenridge AM. Drug interactions with ACE inhibitors. J Hum Hypertens. 1989 Jun;3 Suppl 1:133-8. Review. PubMed PMID: 2674438.
  153. Christie G, Breckenridge AM, Park BK. Drug-protein conjugates–XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem Pharmacol. 1989 May 1;38(9):1451-8. PubMed PMID: 2470378.
  154. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989;36(1):39-46. PubMed PMID: 2917586.
  155. Bem JL, Breckenridge AM, Mann RD, Rawlins MD. Review of yellow cards (1986): report to the Committee on the Safety of Medicines. Br J Clin Pharmacol. 1988 Dec;26(6):679-89. PubMed PMID: 3242573; PubMed Central PMCID: PMC1386581.
  156. Edwards G, Breckenridge AM. Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet. 1988 Aug;15(2):67-93. Review. PubMed PMID: 3064952.
  157. Karbwang J, Back DJ, Bunnag D, Breckenridge AM. Inhibition of tolbutamide metabolism by antimalarial drugs. Southeast Asian J Trop Med Public Health. 1988 Jun;19(2):235-41. PubMed PMID: 3227403.
  158. Back DJ, Grimmer SF, Orme ML, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol. 1988 May;25(5):527-32. PubMed PMID: 3408633; PubMed Central PMCID: PMC1386424.
  159. Winstanley PA, Edwards G, Curtis CG, Orme ML, Powell GM, Breckenridge AM. Tissue distribution and excretion of amodiaquine in the rat. J Pharm Pharmacol. 1988 May;40(5):343-9. PubMed PMID: 2899630.
  160. Christie G, Coleman JW, Newby S, McDiarmaid-Gordon A, Hampson JP, Breckenridge AM, Park BK. A survey of the prevalence of penicillin-specific IgG, IgM and IgE antibodies detected by ELISA and defined by hapten inhibition, in patients with suspected penicillin allergy and in healthy volunteers. Br J Clin Pharmacol. 1988 Mar;25(3):381-6. PubMed PMID: 3358899; PubMed Central PMCID: PMC1386363.
  161. Orme M, Awadzi K, Edwards G, Breckenridge AM. Drug treatment of onchocerciasis. Q J Med. 1988 Mar;66(251):195-201. Review. PubMed PMID: 3059388.
  162. Breckenridge A. Angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed). 1988 Feb 27;296(6622):618-20. Review. PubMed PMID: 2832034; PubMed Central PMCID: PMC2545245.
  163. Vanhoutte P, Amery A, Birkenhäger W, Breckenridge A, Bühler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansson L, et al. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension. 1988 Feb;11(2):111-33. Review. PubMed PMID: 3277910.
  164. Breckenridge A. Current controversies in the treatment of hypertension. Am J Med. 1988 Jan 29;84(1B):36-9. Review. PubMed PMID: 3277417.
  165. Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S, Breckenridge AM, Preston FE, Park BK. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol. 1988 Jan;25(1):1-7. PubMed PMID: 3370190; PubMed Central PMCID: PMC1386607.
  166. Karbwang J, Looareesuwan S, Back DJ, Migasana S, Bunnag D, Breckenridge AM. Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women. Bull World Health Organ. 1988;66(6):763-7. PubMed PMID: 3266115; PubMed Central PMCID: PMC2491144.
  167. Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol. 1988;35(6):681-4. PubMed PMID: 3234475.
  168. Breckenridge A. Ageing, serotonin and ketanserin. Drugs. 1988;36 Suppl 1:44-54. Review. PubMed PMID: 3071462.
  169. Karbwang J, Back DJ, Bunnag D, Breckenridge AM. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur J Clin Pharmacol. 1988;35(6):677-80. PubMed PMID: 3069480.
  170. Breckenridge A. Age-related effects of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol. 1988;12 Suppl 8:S100-4. Review. PubMed PMID: 2469889.
  171. Winstanley PA, Back DJ, Breckenridge AM. Inhibition of theophylline metabolism by interferon. Lancet. 1987 Dec 5;2(8571):1340. PubMed PMID: 2446094.
  172. Richardson PJ, Meany B, Breckenridge AM, Grimmer SF, Johnston GD, Kondowe G. Lisinopril in essential hypertension: a six month comparative study with nifedipine. J Hum Hypertens. 1987 Dec;1(3):175-9. PubMed PMID: 2852252.
  173. Chan E, Aarons L, Serlin M, Breckenridge A, Rowland M. Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. Br J Clin Pharmacol. 1987 Nov;24(5):621-5. PubMed PMID: 3435692; PubMed Central PMCID: PMC1386334.
  174. Nicholl DD, Edwards G, Ward SA, Orme ML, Breckenridge AM. The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. Biochem Pharmacol. 1987 Oct 15;36(20):3365-9. PubMed PMID: 3675598.
  175. Winstanley PA, Breckenridge AM. Currently important antimalarial drugs. Ann Trop Med Parasitol. 1987 Oct;81(5):619-27. Review. PubMed PMID: 3331251.
  176. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet. 1987 Sep 19;2(8560):650-3. PubMed PMID: 2887941.
  177. Roberts DH, Tsao Y, Grimmer SF, Winstanley PA, Orme ML, Breckenridge AM. Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function. Br J Clin Pharmacol. 1987 Aug;24(2):163-72. PubMed PMID: 2887190; PubMed Central PMCID: PMC1387745.
  178. Ward SA, Mihaly GW, Nicholl DD, Breckenridge AM, Edwards G. The pharmacokinetics of (+)- and (-)-primaquine in the isolated perfused rat liver preparation. Biochem Pharmacol. 1987 Jul 1;36(13):2238-9. PubMed PMID: 3606640.
  179. Maggs JL, Kitteringham NR, Breckenridge AM, Park BK. Autoxidative formation of a chemically reactive intermediate from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem Pharmacol. 1987 Jul 1;36(13):2061-2. PubMed PMID: 3606626.
  180. Coleman MD, Edwards G, Braithwaite IM, Breckenridge AM. High-performance liquid chromatographic method for the determination of amopyroquine in biological fluids. J Chromatogr. 1987 Feb 20;414(1):242-7. PubMed PMID: 3571390.
  181. Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol. 1987 Jan;23(1):1-7. PubMed PMID: 3814460; PubMed Central PMCID: PMC1386133.
  182. Winstanley PA, Edwards G, Orme ML, Breckenridge AM. Effect of dose size on amodiaquine pharmacokinetics after oral administration. Eur J Clin Pharmacol. 1987;33(3):331-3. PubMed PMID: 3691624.
  183. Breckenridge A. Factors in the choice of antihypertensive therapy. Br J Clin Pharmacol. 1987;23 Suppl 1:5S-8S. PubMed PMID: 3580258; PubMed Central PMCID: PMC1386040.
  184. Karbwang J, Bunnag D, Breckenridge AM, Back DJ. The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. Eur J Clin Pharmacol. 1987;32(2):173-7. PubMed PMID: 3495440.
  185. Breckenridge A, Orme M, Edwards G. Clinical pharmacology looks at tropical medicine. Trans R Soc Trop Med Hyg. 1987;81(4):529-33. PubMed PMID: 3445331.
  186. Breckenridge A. Enzyme induction in humans. Clinical aspects–an overview. Pharmacol Ther. 1987;33(1):95-9. Review. PubMed PMID: 3306720.
  187. Richardson PJ, Meany TB, Johnston GD, Kondowe G, Grimmer SF, Breckenridge AM. Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial. J Cardiovasc Pharmacol. 1987;10 Suppl 10:S96-8. PubMed PMID: 2455154.
  188. Mörlin C, Baglivo H, Boeijinga JK, Breckenridge AM, Clement D, Johnston GD, Klein W, Kramer R, Luccioni R, Meurer KA, et al. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol. 1987;9 Suppl 3:S49-52. PubMed PMID: 2442552.
  189. Choonara IA, Haynes BP, Cholerton S, Breckenridge AM, Park BK. Enantiomers of warfarin and vitamin K1 metabolism. Br J Clin Pharmacol. 1986 Dec;22(6):729-32. PubMed PMID: 3567019; PubMed Central PMCID: PMC1401216.
  190. Coleman MD, Thompson AJ, Edwards G, Braithwaite IM, Breckenridge AM. The pharmacokinetics of pyrimethamine in the rat: effect of mefloquine. J Pharm Pharmacol. 1986 Nov;38(11):840-2. PubMed PMID: 2879016.
  191. Coleman JW, Yeung JH, Roberts DH, Breckenridge AM, Park BK. Drug-specific antibodies in patients receiving captopril. Br J Clin Pharmacol. 1986 Aug;22(2):161-5. PubMed PMID: 3530304; PubMed Central PMCID: PMC1401103.
  192. Roberts DH, Tsao Y, Breckenridge AM. The reproducibility of limb blood flow measurements in human volunteers at rest and after exercise by using mercury-in-Silastic strain gauge plethysmography under standardized conditions. Clin Sci (Lond). 1986 Jun;70(6):635-8. PubMed PMID: 3709068.
  193. Awadzi K, Adjepon-Yamoah KK, Edwards G, Orme ML, Breckenridge AM, Gilles HM. The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis. Br J Clin Pharmacol. 1986 Jun;21(6):669-76. PubMed PMID: 3017392; PubMed Central PMCID: PMC1400978.
  194. Purba HS, Back DJ, Breckenridge AM. Inhibition of estrogen 2-hydroxylase. J Steroid Biochem. 1986 May;24(5):1091-3. PubMed PMID: 3724146.
  195. Winstanley PA, Edwards G, Orme ML, Breckenridge AM. The detection of amodiaquine in blood after oral administration. Br J Clin Pharmacol. 1986 May;21(5):552. PubMed PMID: 3718814; PubMed Central PMCID: PMC1401019.
  196. Neis AS, Breckenridge AM. Clinical pharmacology teaching, training and career development. Clin Pharmacol Ther. 1986 Apr;39(4):466-70. PubMed PMID: 3956068.
  197. Breckenridge A. Ketanserin–a new antihypertensive agent. J Hypertens Suppl. 1986 Apr;4(1):S13-6. PubMed PMID: 2871143.
  198. Park BK, Choonara IA, Haynes BP, Breckenridge AM, Malia RG, Preston FE. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol. 1986 Mar;21(3):289-93. PubMed PMID: 3964529; PubMed Central PMCID: PMC1400858.
  199. Coleman MD, Mihaly GW, Edwards G, Howells RE, Breckenridge AM. The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. Biopharm Drug Dispos. 1986 Mar-Apr;7(2):173-82. PubMed PMID: 3708123.
  200. Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol. 1986 Mar;21(3):271-7. PubMed PMID: 2938614; PubMed Central PMCID: PMC1400859.
  201. Breckenridge AM. The pharmaceutical industry and developing countries. Br J Clin Pharmacol. 1986;22 Suppl 1:27S-29S. PubMed PMID: 3567027; PubMed Central PMCID: PMC1400997.
  202. Choonara IA, Scott AK, Haynes BP, Cholerton S, Breckenridge AM, Park BK. Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. Br J Clin Pharmacol. 1985 Dec;20(6):643-8. PubMed PMID: 4091996; PubMed Central PMCID: PMC1400816.
  203. Coleman MD, Mihaly GW, Ward SA, Edwards G, Howells RE, Breckenridge AM. The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. J Pharm Pharmacol. 1985 Dec;37(12):878-83. PubMed PMID: 2868095.
  204. Breckenridge A. Decision-making in the development of new drugs. J Hypertens Suppl. 1985 Nov;3(2):S51-5. PubMed PMID: 3910776.
  205. Rivière JH, Back DJ, Breckenridge AM, Howells RE. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. Br J Clin Pharmacol. 1985 Nov;20(5):469-74. PubMed PMID: 3878153; PubMed Central PMCID: PMC1400721.
  206. Edwards G, Rodick CL, Ward SA, Awadzi K, Orme ML, Breckenridge AM. Determination of suramin in plasma by high-performance liquid chromatography. J Chromatogr. 1985 Sep 13;343(1):224-8. PubMed PMID: 4066859.
  207. Breckenridge A. Treating mild hypertension. Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):89-90. PubMed PMID: 3926098; PubMed Central PMCID: PMC1416281.
  208. Winstanley PA, Tjia J, Back DJ, Hobson D, Breckenridge AM. Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism. Br J Clin Pharmacol. 1985 Jul;20(1):47-53. PubMed PMID: 4027135; PubMed Central PMCID: PMC1400622.
  209. Ward SA, Mihaly GW, Nicholl DD, Edwards G, Breckenridge AM. The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. Drug Metab Dispos. 1985 Jul-Aug;13(4):425-9. PubMed PMID: 2863105.
  210. Coleman MD, Mihaly GW, Ward SA, Edwards G, Howells RE, Breckenridge AM. The disposition of pyrimethamine in the isolated perfused rat liver. Biochem Pharmacol. 1985 Jun 15;34(12):2193-7. PubMed PMID: 4004937.
  211. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol. 1985 Jun;19(6):751-5. PubMed PMID: 4027118; PubMed Central PMCID: PMC1463877.
  212. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985 Jun;19(6):745-50. PubMed PMID: 4027117; PubMed Central PMCID: PMC1463857.
  213. Breckenridge A, Woolfson AM. [Drugs and fluids for the intravenous route]. Riv Inferm. 1985 Mar;4(1):11-3. Italian. PubMed PMID: 3933081.
  214. Coleman MD, Mihaly GW, Edwards G, Ward SA, Howells RE, Breckenridge AM. Pyrimethamine pharmacokinetics and its tissue localization in mice: effect of dose size. J Pharm Pharmacol. 1985 Mar;37(3):170-4. PubMed PMID: 2858563.
  215. Mihaly GW, Ward SA, Nicholl DD, Edwards G, Breckenridge AM. The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes. Biochem Pharmacol. 1985 Feb 1;34(3):331-6. PubMed PMID: 3970715.
  216. Mihaly GW, Nicholl DD, Edwards G, Ward SA, Orme ML, Warrell DA, Breckenridge AM. High-performance liquid chromatographic analysis of amodiaquine in human plasma. J Chromatogr. 1985 Jan 11;337(1):166-71. PubMed PMID: 3980649.
  217. Breckenridge AM, Cholerton S, Hart JA, Park BK, Scott AK. A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. Br J Pharmacol. 1985 Jan;84(1):81-91. PubMed PMID: 3978316; PubMed Central PMCID: PMC1987219.
  218. Breckenridge A. Angiotensin converting enzyme inhibition in clinical practice. Re-examination of step care: choice of first drug. J Cardiovasc Pharmacol. 1985;7 Suppl 1:S117-20. PubMed PMID: 2580163.
  219. Park BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol. 1984 Nov;18(5):655-62. PubMed PMID: 6508974; PubMed Central PMCID: PMC1463546.
  220. Breckenridge A. The third drug in hypertension. Br Med J (Clin Res Ed). 1984 Oct 6;289(6449):859-60. PubMed PMID: 6148121; PubMed Central PMCID: PMC1443384.
  221. Breckenridge A, Woolfson AM. Drugs and intravenous fluids. Br Med J (Clin Res Ed). 1984 Sep 15;289(6446):637-8. PubMed PMID: 6434018; PubMed Central PMCID: PMC1443095.
  222. Back DJ, Breckenridge AM, Grimmer SF, Orme ML, Purba HS. Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine. Contraception. 1984 Sep;30(3):289-95. PubMed PMID: 6439467.
  223. Coleman MD, Edwards G, Mihaly GW, Howells RE, Breckenridge AM. High-performance liquid chromatographic method for the determination of pyrimethamine and its 3-N-oxide metabolite in biological fluids. J Chromatogr. 1984 Jun 8;308:363-9. PubMed PMID: 6746829.
  224. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol. 1984 May;17(5):559-64. PubMed PMID: 6733003; PubMed Central PMCID: PMC1463461.
  225. Breckenridge A. Clinical pharmacology. Lancet. 1984 Apr 7;1(8380):796-7. PubMed PMID: 6143117.
  226. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol. 1984 Apr;17(4):441-6. PubMed PMID: 6721990; PubMed Central PMCID: PMC1463409.
  227. Breckenridge A, Awadzi K, Back DJ, Edwards G, Gilles H, Orme M, Ward S. Drug metabolism and tropical disease. Biochem Soc Trans. 1984 Feb;12(1):90-5. PubMed PMID: 6705997.
  228. Back DJ, Breckenridge A, Orme M, Shaw MA. Pharmacokinetic and “potency” of contraceptive steroids. Lancet. 1984 Jan 21;1(8369):171. PubMed PMID: 6140487.
  229. Ward SA, Edwards G, Orme ML, Breckenridge AM. Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr. 1984 Jan 13;305(1):239-43. PubMed PMID: 6707149.
  230. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol. 1984;17 Suppl 1:86S. PubMed PMID: 6743477; PubMed Central PMCID: PMC1463272.
  231. Yeung JH, Breckenridge AM, Park BK. Drug protein conjugates–VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. Biochem Pharmacol. 1983 Dec 1;32(23):3619-25. PubMed PMID: 6360177.
  232. Breckenridge A. Compliance of hypertensive patients with pharmacological treatment. Hypertension. 1983 Sep-Oct;5(5 Pt 2):III85-9. PubMed PMID: 6629467.
  233. Yeung JH, Breckenridge AM, Park BK. Drug-protein conjugates–IV. The effect of acute renal failure on the disposition of [14C]captopril in the rat. Biochem Pharmacol. 1983 Sep 1;32(17):2467-72. PubMed PMID: 6351864.
  234. Maggs JL, Grimmer SF, Orme ML, Breckenridge AM, Park BK, Gilmore IT. The biliary and urinary metabolites of [3H]17 alpha-ethynylestradiol in women. Xenobiotica. 1983 Jul;13(7):421-31. PubMed PMID: 6659545.
  235. Grimmer SF, Allen WL, Back DJ, Breckenridge AM, Orme M, Tjia J. The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception. 1983 Jul;28(1):53-9. PubMed PMID: 6414761.
  236. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs. 1983 Jun;25(6):610-20. Review. PubMed PMID: 6347619.
  237. Serlin MJ, Orme ML, MacIver M, Green GJ, Sibeon RG, Breckenridge AM. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol. 1983 May;15(5):519-27. PubMed PMID: 6860527; PubMed Central PMCID: PMC1427717.
  238. Breckenridge A. Which beta blocker? Br Med J (Clin Res Ed). 1983 Apr 2;286(6371):1085-8. Review. PubMed PMID: 6132652; PubMed Central PMCID: PMC1547455.
  239. Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet. 1983 Mar-Apr;8(2):95-136. Review. PubMed PMID: 6342899.
  240. Back DJ, Breckenridge AM, Orme ML. Drug interactions with oral contraceptive steroids. IPPF Med Bull. 1983 Feb;17(1):1-2. PubMed PMID: 12264750.
  241. Back DJ, Purba HS, Staiger C, Orme ML, Breckenridge AM. Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochem Pharmacol. 1983 Jan 15;32(2):257-63. PubMed PMID: 6870955.
  242. Awadzi K, Orme ML, Breckenridge AM, Gilles HM. The chemotherapy of onchocerciasis IX. The effect of prednisone plus cyproheptadine on the Mazzotti reaction. Ann Trop Med Parasitol. 1982 Oct;76(5):547-55. PubMed PMID: 6760823.
  243. Breckenridge A. Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint. Br Med J (Clin Res Ed). 1982 Jul 3;285(6334):37-9. PubMed PMID: 6123366; PubMed Central PMCID: PMC1499133.
  244. Back DJ, Breckenridge AM, MacIver M, Orme M, Rowe PH, Staiger C, Thomas E, Tjia J. The effects of ampicillin on oral contraceptive steroids in women. Br J Clin Pharmacol. 1982 Jul;14(1):43-8. PubMed PMID: 6809025; PubMed Central PMCID: PMC1427567.
  245. Adjepon-Yamoah KK, Edwards G, Breckenridge AM, Orme ML, Ward SA. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man. Br J Clin Pharmacol. 1982 Jun;13(6):829-34. PubMed PMID: 7093114; PubMed Central PMCID: PMC1402015.
  246. Awadzi K, Orme ML, Breckenridge AM, Gilles HM. The chemotherapy of onchocerciasis VII. The effect of prednisone on the Mazzotti reaction. Ann Trop Med Parasitol. 1982 Jun;76(3):331-8. PubMed PMID: 6751250.
  247. Awadzi K, Orme ML, Breckenridge AM, Gilles HM. The chemotherapy of onchocerciasis VI. The effect of indomethacin and cyproheptadine on the Mazzotti reaction. Ann Trop Med Parasitol. 1982 Jun;76(3):323-30. PubMed PMID: 6751249.
  248. Breckenridge A, Orme M, Serlin MJ, Maciver M. Labetalol in essential hypertension. Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):37S-39S. PubMed PMID: 6124264; PubMed Central PMCID: PMC1401833.
  249. Park BK, Grabowski PS, Yeung JH, Breckenridge AM. Drug protein conjugates–I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat. Biochem Pharmacol. 1982 May 1;31(9):1755-60. PubMed PMID: 7049181.
  250. Breckenridge A. Vasodilators in heart failure. Br Med J (Clin Res Ed). 1982 Mar 13;284(6318):765-6. PubMed PMID: 6802217; PubMed Central PMCID: PMC1496367.
  251. Crawford FE, Back DJ, Orme ML, Breckenridge AM. [Oral contraceptive steroid plasma concentrations in smokers and non-smokers (author’s transl)]. Contracept Fertil Sex (Paris). 1982 Mar;10(3):143-8. French. PubMed PMID: 12264081.
  252. Back DJ, Barkfeldt JO, Breckenridge AM, Odlind V, Orme M, Park BK, Purba H, Tjia J, Victor A. The enzyme inducing effect of rifampicin in the rhesus monkey and its lack of interaction with oral contraceptive steroids. Contraception. 1982 Mar;25(3):307-16. PubMed PMID: 7075197.
  253. Back DJ, Breckenridge AM, MacIver M, Orme M, Purba HS, Rowe PH, Taylor I. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. Br J Clin Pharmacol. 1982 Mar;13(3):325-30. PubMed PMID: 7059434; PubMed Central PMCID: PMC1402099.
  254. Breckenridge A. Jogger’s blockade. Br Med J (Clin Res Ed). 1982 Feb 20;284(6315):532-3. PubMed PMID: 6120740; PubMed Central PMCID: PMC1496175.
  255. Edwards G, Breckenridge AM, Adjepon-Yamoah KK, Orme ML, Ward SA. The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine. Br J Clin Pharmacol. 1981 Dec;12(6):807-12. PubMed PMID: 7340883; PubMed Central PMCID: PMC1401934.
  256. Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981 Dec;12(6):791-4. PubMed PMID: 6122462; PubMed Central PMCID: PMC1401939.
  257. Maskill MR, Orme ML, MacIver M, Serlin MJ, Breckenridge AM. Efficacy and adverse effects of captopril in severe refractory hypertension. J Cardiovasc Pharmacol. 1981 Nov-Dec;3(6):1287-95. PubMed PMID: 6173529.
  258. Back DJ, Breckenridge AM, Crawford FE, Giles M, Orme ML, Rowe PH. The pharmacokinetics of oestrone sulphate in the rat. J Steroid Biochem. 1981 Oct;14(10):1045-7. PubMed PMID: 7300324.
  259. Edwards G, Awadzi K, Breckenridge AM, Gilles HM, Orme ML, Ward SA. Diethylcarbamazine disposition in patients with onchocerciasis. Clin Pharmacol Ther. 1981 Oct;30(4):551-7. PubMed PMID: 7285488.
  260. Crawford FE, Back DJ, Orme ML, Breckenridge AM. Oral contraceptive steroid plasma concentrations in smokers and non-smokers. Br Med J (Clin Res Ed). 1981 Jun 6;282(6279):1829-30. PubMed PMID: 6786637; PubMed Central PMCID: PMC1506412.
  261. Back DJ, Breckenridge AM, MacIver M, Orme ML, Purba H, Rowe PH. Interaction of ethinyloestradiol with ascorbic acid in man. Br Med J (Clin Res Ed). 1981 May 9;282(6275):1516. PubMed PMID: 6786543; PubMed Central PMCID: PMC1505474.
  262. Edwards G, Ward SA, Breckenridge AM, Orme ML. Identification and quantification of diethylcarbamazine and diethylcarbamazine N-oxide in rat urine. Xenobiotica. 1981 Apr;11(4):281-4. PubMed PMID: 7303719.
  263. Back DJ, Bates M, Breckenridge AM, Hall JM, MacIver M, Orme ML, Park BK, Rowe PH. The pharmacokinetics of levonorgestrel and ethynylestradiol in women – studies with Ovran and Ovranette. Contraception. 1981 Mar;23(3):229-39. PubMed PMID: 6786829.
  264. Back DJ, Bates M, Breckenridge AM, Ellis A, Hall JM, Maciver M, Orme ML, Rowe PH. The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa. Br J Clin Pharmacol. 1981 Mar;11(3):275-8. PubMed PMID: 6783058; PubMed Central PMCID: PMC1401625.
  265. Back DJ, Breckenridge AM, Chapman CR, Crawford FE, Olsen KA, Orme ML, Rowe PH. Studies on the enzymatic cleavage of norethisterone oenanthate. Contraception. 1981 Feb;23(2):125-32. PubMed PMID: 7238040.
  266. Awadzi K, Orme ML, Breckenridge AM, Haddock D, Gilles HM. Studies of metrifonate in onchocerciasis. Acta Pharmacol Toxicol (Copenh). 1981;49 Suppl 5:131-6. PubMed PMID: 7344407.
  267. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs. 1981 Jan;21(1):46-61. Review. PubMed PMID: 7009137.
  268. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet. 1981 Jan-Feb;6(1):1-24. Review. PubMed PMID: 6113907.
  269. Back DJ, Bates M, Bowden A, Breckenridge AM, Hall MJ, Jones H, MacIver M, Orme M, Perucca E, Richens A, Rowe PH, Smith E. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception. 1980 Nov;22(5):495-503. PubMed PMID: 7471739.
  270. Kinzie JD, Tran KA, Breckenridge A, Bloom JD. An Indochinese refugee psychiatric clinic: culturally accepted treatment approaches. Am J Psychiatry. 1980 Nov;137(11):1429-32. PubMed PMID: 7435679.
  271. Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interaction between diflunisal and warfarin. Clin Pharmacol Ther. 1980 Oct;28(4):493-8. PubMed PMID: 7408409.
  272. Back DJ, Breckenridge AM, Crawford FE, Orme ML, Rowe PH. Phenobarbitone interaction with oral contraceptive steroids in the rabbit and rat. Br J Pharmacol. 1980 Jul;69(3):441-52. PubMed PMID: 7397454; PubMed Central PMCID: PMC2044275.
  273. Serlin MJ, Challiner M, Park BK, Turcan PA, Breckenridge AM. Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol. 1980 Jul 1;29(13):1971-2. PubMed PMID: 7397004.
  274. Park BK, Leck JB, Breckenridge AM. The dose-dependent effect of warfarin on vitamin K1 metabolism and clotting factor synthesis in the rabbit. Biochem Pharmacol. 1980 Jun 1;29(11):1601-2. PubMed PMID: 7396990.
  275. Breckenridge AM. Assessment of new drugs: a clinical pharmacologist’s view. Br Med J. 1980 May 31;280(6227):1303-5. PubMed PMID: 6992929; PubMed Central PMCID: PMC1601606.
  276. Breckenridge A. Antipyrine half-life and drug elimination. Clin Pharmacokinet. 1980 May-Jun;5(3):201-3. PubMed PMID: 7389234.
  277. Serlin MJ, Orme ML, Baber NS, Sibeon RG, Laws E, Breckenridge A. Propranolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther. 1980 May;27(5):586-92. PubMed PMID: 6102895.
  278. Serlin MJ, Mossman S, Sibeon RG, Breckenridge AM. The effect of diflunisal on the steady state pharmacodynamics and pharmacokinetics of warfarin [proceedings]. Br J Clin Pharmacol. 1980 Mar;9(3):287P-288P. PubMed PMID: 7362744.
  279. Back DJ, Bates M, Breckenridge AM, Crawford FE, Ellis A, Hall JM, Maciver M, Orme ML, Rowe PH. The in vitro metabolism of ethinyloestradiol, levonorgestrel and mestranol by human jejunal mucosa [proceedings]. Br J Clin Pharmacol. 1980 Mar;9(3):281P-282P. PubMed PMID: 7362737; PubMed Central PMCID: PMC1429878.
  280. Back DJ, Bolt HM, Breckenridge AM, Crawford FE, Orme ML, Rowe PH, Schindler AE. The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. Contraception. 1980 Feb;21(2):145-53. PubMed PMID: 7371408.
  281. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme ML, Rowe PH, Smith E, Watts MJ. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception. 1980 Feb;21(2):135-43. PubMed PMID: 7189454.
  282. Back DJ, Breckenridge AM, Crawford FE, Cross KJ, Orme ML, Percival A, Rowe PH. Reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat: correlation with changes in the gut flora. J Steroid Biochem. 1980 Jan;13(1):95-100. PubMed PMID: 7382487.
  283. Back DJ, Breckenridge AM, Crawford FE, Cross KJ, Orme ML, Rowe PH. The interaction of antibiotics with ethinyloestradiol in the rat and rabbit [proceedings]. Br J Pharmacol. 1980 Jan;68(1):118P. PubMed PMID: 7357138; PubMed Central PMCID: PMC2044067.
  284. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Perucca E, Richens A, Rowe PH, Smith E. The effect of oral contraceptive steroids and enzyme inducing drugs on sex hormone binding globulin capacity in women [proceedings]. Br J Clin Pharmacol. 1980 Jan;9(1):115P. PubMed PMID: 7188852.
  285. Breckenridge AM, Back DJ, Cross K, Crawford F, MacIver M, Orme ML, Rowe PH, Smith E. Influence of environmental chemicals on drug therapy in humans: studies with contraceptive steroids. Ciba Found Symp. 1980;76:289-306. PubMed PMID: 6906266.
  286. Green GJ, Wilson H, Breckenridge AM. Action of clonidine on centrally evoked salivation in anaesthetized cats. Clin Sci (Lond). 1979 Dec;57 Suppl 5:429s-431s. PubMed PMID: 540464.
  287. Back DJ, Bates M, Burke MW, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH, Smith E, Webster S. Plasma Xa inhibitory activities and plasma concentrations of norgestrel and ethinyloestradiol in women on oral contraceptive steroids. Br J Clin Pharmacol. 1979 Nov;8(5):505-6. PubMed PMID: 508558; PubMed Central PMCID: PMC1429815.
  288. Breckenridge AM, Orme ML. Digitalis and other cardiac glycosides. Practitioner. 1979 Oct;223(1336):465-9. PubMed PMID: 523400.
  289. Breckenridge AM, Challiner M, Mossman S, Park BK, Serlin MJ, Sibeon RG, Williams JR, Willoughby JM. Cimetidine increases the action of warfarin in man [proceedings]. Br J Clin Pharmacol. 1979 Oct;8(4):392P-393P. PubMed PMID: 508530.
  290. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH, Watts MJ. An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception. 1979 Sep;20(3):263-73. PubMed PMID: 509953.
  291. Park BK, Breckenridge AM, Ohnhaus EE. [Modification of the action of drugs by inhibition of their metabolism]. Recenti Prog Med. 1979 Sep;67(3):313-45. Review. Italian. PubMed PMID: 42953.
  292. Serlin MJ, Sibeon RG, Mossman S, Breckenridge AM, Williams JR, Atwood JL, Willoughby JM. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979 Aug 18;2(8138):317-9. PubMed PMID: 89387.
  293. Orme ML, Serlin MJ, Breckenridge A. Thromboembolism in pregnancy. Br Med J. 1979 Aug 4;2(6185):333. PubMed PMID: 476455; PubMed Central PMCID: PMC1595688.
  294. Back DJ, Bolt HM, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH, Schindler AE, Smith E. The pharmacokinetics of ethinyloestradiol in women [proceedings]. Br J Pharmacol. 1979 Jul;66(3):441P-442P. PubMed PMID: 526731; PubMed Central PMCID: PMC2043750.
  295. Breckenridge AM. Editorial independence of prescribers’ journal. Lancet. 1979 Jun 16;1(8129):1296. PubMed PMID: 87757.
  296. Green CJ, Breckenridge AM, Wright FK. Severe orthostatic hypotension associated with carcinoma of the bronchus. Postgrad Med J. 1979 Jun;55(644):426-9. PubMed PMID: 225737; PubMed Central PMCID: PMC2425584.
  297. Back DJ, Breckenridge AM, Crawford F, MacIver M, Orme ML, Park BK, Rowe PH, Smith E. The effect of rifampicin on norethisterone pharmacokinetics. Eur J Clin Pharmacol. 1979 Apr 17;15(3):193-7. PubMed PMID: 37091.
  298. Park BK, Leck JB, Wilson AC, Serlin MJ, Breckenridge AM. A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol. 1979 Apr 15;28(8):1323-9. PubMed PMID: 444299.
  299. Breckenridge AM. Drug-induced cardiovascular disease. Br Med J. 1979 Mar 24;1(6166):793-5. PubMed PMID: 435800; PubMed Central PMCID: PMC1598401.
  300. Serlin MJ, Orme MC, Maciver M, Green GJ, Macnee CM, Breckenridge AM. Rate of onset of hypotensive effect of oral labetalol. Br J Clin Pharmacol. 1979 Feb;7(2):165-8. PubMed PMID: 760748; PubMed Central PMCID: PMC1429443.
  301. Vose CW, Butler JK, Williams BM, Stafford JE, Shelton JR, Rose DA, Palmer RF, Breckenridge AM, Orme ML, Serlin MJ. Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. Contraception. 1979 Feb;19(2):119-27. PubMed PMID: 428229.
  302. Breckenridge AM, Back DJ, Orme M. Interactions between oral contraceptives and other drugs. Pharmacol Ther. 1979;7(3):617-26. Review. PubMed PMID: 392564.
  303. Back DJ, Breckenridge AM, Crawford FE, Orme ML, Rowe PH, Sloan TP, Smith E. The pharmacokinetics of tritiated ethinylestradiol in the rabbit. Steroids. 1978 Nov;32(4):423-33. PubMed PMID: 725974.
  304. Back DJ, Breckenridge AM, Cross KJ, Orme ML, Percival A, Rowe PH. The reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat [proceedings]. Br J Pharmacol. 1978 Nov;64(3):401P. PubMed PMID: 719259; PubMed Central PMCID: PMC1668572.
  305. Breckenridge AM, Leck JB, Park BK, Serlin MJ, Wilson A. Mechanisms of action of the anticoagulants warfarin, 2-chloro-3-phytylnaphthoquinone (Cl-K), acenocoumarol, brodifacoum and difenacoum in the rabbit [proceedings]. Br J Pharmacol. 1978 Nov;64(3):399P. PubMed PMID: 719257; PubMed Central PMCID: PMC1668514.
  306. Back DJ, Breckenridge AM, Crawford FE, Orme ML, Rowe PH, Smith E. First-pass effect of norethindrone in rabbits and rats. J Pharmacol Exp Ther. 1978 Nov;207(2):555-65. PubMed PMID: 712638.
  307. Back DJ, Breckenridge AM, Crawford FE, Mciver M, Orme ML, Rowe PH, Smith E. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther. 1978 Oct;24(4):448-53. PubMed PMID: 688734.
  308. Back DJ, Breckenridge AM, Crawford FE, Mciver M, Orme ML, Park BK, Rowe PH, Smith E. Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing. Clin Pharmacol Ther. 1978 Oct;24(4):439-47. PubMed PMID: 567550.
  309. Back DJ, Breckenridge AM, Crawford FE, Cross KJ, Orme ML, Rowe PH, Smith E, Todd K. Biliary excretion of synthetic sex steroids in heterozygous and homozygous Gunn rats. Life Sci. 1978 Sep 11;23(10):1053-6. PubMed PMID: 101724.
  310. Breckenridge A, Orme M, Serlin MJ, Davidson AS, Lowe JF. Postgraduate education in therapeutics: experience in Merseyside. Br Med J. 1978 Sep 2;2(6138):671-2. PubMed PMID: 698659; PubMed Central PMCID: PMC1607420.
  311. Back DJ, Breckenridge AM. Drug interactions with oral contraceptives. IPPF Med Bull. 1978 Aug;12(4):1-2. PubMed PMID: 689274.
  312. Back DJ, Bates MW, Breckenridge AM, Crawford FE, Orme ML, Rowe PH, Smiles G, Smith E. Ethynylestradiol and norethindrone metabolism by everted sacs of rat ileum. Contraception. 1978 Aug;18(2):127-35. PubMed PMID: 688750.
  313. O’Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol. 1978 Aug;6(2):176-7. PubMed PMID: 678394; PubMed Central PMCID: PMC1429416.
  314. Back DJ, Breckenridge AM, Challiner M, Crawford FE, Orme ML, Rowe PH, Smith E. The effect of antibiotics on the enterohepatic circulation of ethinylestradiol and norethisterone in the rat. J Steroid Biochem. 1978 Jun;9(6):527-31. PubMed PMID: 692118.
  315. Back DJ, Breckenridge AM, Challiner M, Crawford FE, Orme ML, Rowe PH, Smith E. The interaction of antibiotics with synthetic steroids in the rat [proceedings]. Br J Pharmacol. 1978 Mar;62(3):441P. PubMed PMID: 638363; PubMed Central PMCID: PMC1668142.
  316. Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol. 1978 Jan;15(1):19-26. Review. PubMed PMID: 341326.
  317. Breckenridge AM. Interindividual differences in the response to oral anticoagulants. Drugs. 1977 Nov;14(5):367-75. Review. PubMed PMID: 338281.
  318. Breckenridge A, Calvey TN, Green GJ, McIver M, Orme ML, Serlin MJ. Labetalol in hypertension. Lancet. 1977 Jul 2;2(8027):36. PubMed PMID: 69119.
  319. Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, Breckenridge AM. May mothers given warfarin breast-feed their infants? Br Med J. 1977 Jun 18;1(6076):1564-5. PubMed PMID: 871666; PubMed Central PMCID: PMC1607348.
  320. Breckenridge AM, Macnee CM, Orme NL, Richards DA, Sterlin MJ. Rate of onset of hypotensive response with oral labetalol [proceedings]. Br J Clin Pharmacol. 1977 Jun;4(3):388P. PubMed PMID: 901712.
  321. Shearer MJ, McBurney A, Breckenridge AM, Barkhan P. Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man. Clin Sci Mol Med. 1977 Jun;52(6):621-30. PubMed PMID: 884934.
  322. Back DJ, Breckenridge AM, Gay FE, Orme ML’E, Rowe PH, Smith E. The pharmacokinetics of norethisterone in the rabbit and rat after systemic and oral administration: effect of phenobarbitone [proceedings]. Br J Pharmacol. 1977 Jun;60(2):279P. PubMed PMID: 880448; PubMed Central PMCID: PMC1667472.
  323. Breckenridge A. Drug interactions during metabolism in the liver. Naunyn Schmiedebergs Arch Pharmacol. 1977;297 Suppl 1:S33-4. PubMed PMID: 859652.
  324. Marsh AR, Fraser HS, Breckenridge A, Lewis B, Thompson GR. Accentuation of ethanol-induced fatty liver by phenobarbitone. Clin Sci Mol Med. 1977 Feb;52(2):219-22. PubMed PMID: 844254.
  325. Orme M, Breckenridge A. Enantiomers of warfarin and phenobarbital. N Engl J Med. 1976 Dec 23;295(26):1482-3. PubMed PMID: 995149.
  326. Bulpitt CJ, Breckenridge A. Plasma urea in hypertensive patients. Br Heart J. 1976 Jul;38(7):689-94. PubMed PMID: 973892; PubMed Central PMCID: PMC483068.
  327. Breckenridge AM, Roberts JB. Clinical significance of microsomal enzyme induction. Pharmacol Res Commun. 1976 Jun;8(3):229-42. PubMed PMID: 1026955.
  328. Breckenridge AM, Baker JA. Letter: Addition of drugs to intravenous fluids. Lancet. 1976 May 22;1(7969):1127-8. PubMed PMID: 57530.
  329. Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A. Effects of methyldopa on prolactin and growth hormone. Br Med J. 1976 May 15;1(6019):1186-8. PubMed PMID: 1268617; PubMed Central PMCID: PMC1639736.
  330. Pearson RM, Bending MR, Bulpitt CJ, George CF, Hole DR, Williams FM, Breckenridge AM. Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J. 1976 Apr 17;1(6015):933-6. PubMed PMID: 773486; PubMed Central PMCID: PMC1639247.
  331. Breckenridge A. Oral anticoagulants–the totem and the taboo. Br Med J. 1976 Feb 21;1(6007):419-23. PubMed PMID: 766893; PubMed Central PMCID: PMC1638959.
  332. George CF, Orme ML, Buranapong P, Macerlean D, Breckenridge AM, Dollery CT. Contribution of the liver to overall elimination of propranolol. J Pharmacokinet Biopharm. 1976 Feb;4(1):17-27. PubMed PMID: 1271238.
  333. Pearson RM, Breckenridge AM. Renal function, protein binding and pharmacological response to diazoxide. Br J Clin Pharmacol. 1976 Feb;3(1):169-75. PubMed PMID: 973937; PubMed Central PMCID: PMC1428802.
  334. Orme M, Breckenridge A, Cook P. Warfarin and Distalgesic interaction. Br Med J. 1976 Jan 24;1(6003):200. PubMed PMID: 1247776; PubMed Central PMCID: PMC1638479.
  335. Shearer MJ, McBurney A, Breckenridge A, Barkhan P. Dose – response relationship between warfarin and the metabolism of phylloquinone (vitamin K1) in man. Int J Vitam Nutr Res. 1976;46(2):215-9. PubMed PMID: 1032634.
  336. Breckenridge AM. Proceedings: Are drug interactions important? Arzneimittelforschung. 1976;26(6):1260-1. PubMed PMID: 989457.
  337. Breckenridge A, Orme M, Rowland M, Shearer M, Lewis RJ. Proceedings: Alterations in the response to warfarin. Acta Pharm Suec. 1974 Dec;11(6):652-3. PubMed PMID: 1136804.
  338. Breckenridge A. Clinical implications of enzyme induction. Basic Life Sci. 1975;6:273-301. Review. PubMed PMID: 239673.
  339. Breckenridge A. Interactions with warfarin. Br J Clin Pharmacol. 1974 Aug;1(4):285-6. PubMed PMID: 22454879; PubMed Central PMCID: PMC1402426.
  340. Vajda F, Williams FM, Davidson S, Falconer MA, Breckenridge A. Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther. 1974 Jun;15(6):597-603. PubMed PMID: 4841972.
  341. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M, Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974 Jun;53(6):1607-17. PubMed PMID: 4830225; PubMed Central PMCID: PMC302656.
  342. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974 Apr;15(4):424-30. PubMed PMID: 4821443.
  343. Orme ML, Davies L, Breckenridge A. Increased glucuronidation of bilirubin in man and rat by administration of antipyrine (phenazone). Clin Sci Mol Med. 1974 Apr;46(4):511-8. PubMed PMID: 4208404.
  344. Breckenridge A. Anticonvulsant pharmacokinetics. Proc R Soc Med. 1974 Jan;67(1):63-4. Review. PubMed PMID: 4595345; PubMed Central PMCID: PMC1645667.
  345. Pearson RM, Bulpitt C, George CF, Hole D, Breckenridge A. Proceedings: A trial of the combination of guanethidine and oxprenolol in hypertension. Scott Med J. 1974 Jan;19(1):45-6. PubMed PMID: 4594824.
  346. George CF, Breckenridge AM, Dollery CT. Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia. Lancet. 1973 Dec 8;2(7841):1288-91. PubMed PMID: 4127641.
  347. Breckenridge A, Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):955-61. PubMed PMID: 4584153.
  348. Orme ML, Breckenridge A, Dollery CT. The effects of long term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol. 1973 Oct;6(3):150-5. PubMed PMID: 4586848.
  349. Breckenridge A, Orme ML, Davies L, Thorgeirsson SS, Davies DS. Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514-20. PubMed PMID: 4723259.
  350. Breckenridge A, Buranapong P, Dollery CT, George CF, Macerlean D, Orme ML. Hepatic clearance of propranolol in dogs. Br J Pharmacol. 1973 Jun;48(2):336P-337P. PubMed PMID: 4733741; PubMed Central PMCID: PMC1776197.
  351. Breckenridge A, Davies DS, Davies L, Orme M. Dose-dependent enzyme induction. Br J Pharmacol. 1973 Mar;47(3):616P-617P. PubMed PMID: 4730838; PubMed Central PMCID: PMC1776330.
  352. Lewis PJ, Archer DF, Breckenridge A. Simultaneous onset of malignant hypertension in identical twins. Br Heart J. 1973 Mar;35(3):347-8. PubMed PMID: 4266342; PubMed Central PMCID: PMC458614.
  353. Whitfield JB, Moss DW, Neale G, Orme M, Breckenridge A. Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J. 1973 Feb 10;1(5849):316-8. PubMed PMID: 4405530; PubMed Central PMCID: PMC1588204.
  354. Breckenridge A, Burke CW, Davies DS, Orme ML. Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol. 1973 Feb;47(2):434-6. PubMed PMID: 4722054; PubMed Central PMCID: PMC1776537.
  355. Davies DS, Thorgeirsson SS, Breckenridge A, Orme M. Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos. 1973 Jan-Feb;1(1):411-7. PubMed PMID: 4149412.
  356. Orme M, Breckenridge A, Brooks RV. Interactions of benzodiazepines with warfarin. Br Med J. 1972 Sep 9;3(5827):611-4. PubMed PMID: 5071697; PubMed Central PMCID: PMC1785896.
  357. George CF, Breckenridge AM, Dollery CT. Value of routine electrocardiography in hypertensive patients. Br Heart J. 1972 Jun;34(6):618-22. PubMed PMID: 4261115; PubMed Central PMCID: PMC458509.
  358. Breckenridge A, Orme ML. The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II. 1972 Apr 8;11(7):337-45. PubMed PMID: 4656510.
  359. Silver J, Neale G, Davies D, Breckenridge A, Thompson GR. The effect of phenobarbitone-induction on vitamin D metabolism. Clin Sci. 1972 Feb;42(2):12P. PubMed PMID: 4333647.
  360. Ohnhaus EE, Thorgeirsson SS, Davies DS, Breckenridge A. Changes in liver blood flow during enzyme induction. Biochem Pharmacol. 1971 Oct;20(10):2561-70. PubMed PMID: 5114497.
  361. Breckenridge A, Orme M. Clinical implications of enzyme induction. Ann N Y Acad Sci. 1971 Jul 6;179:421-31. PubMed PMID: 5285387.
  362. Breckenridge A, Orme ML, Thorgeirsson S, Davies DS, Brooks RV. Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci. 1971 Apr;40(4):351-64. PubMed PMID: 5575281.
  363. Breckenridge A, Rosen A. The binding of chlorothiazide to plasma proteins. Biochim Biophys Acta. 1971 Mar 23;229(3):610-7. PubMed PMID: 5555213.
  364. Breckenridge A. Prognosis of treated hypertension. Br Heart J. 1971;33:Suppl:127-8. PubMed PMID: 5572637; PubMed Central PMCID: PMC503285.
  365. Breckenridge A. Pathophysiological factors influencing drug kinetics. Acta Pharmacol Toxicol (Copenh). 1971;29 Suppl 3:225-32. PubMed PMID: 5316404.
  366. Ohnhaus EE, Emons E, Breckenridge A. Long term liver blood flow measurements in rats under physiological conditions. Pflugers Arch. 1971;323(2):182-6. PubMed PMID: 5101238.
  367. Orme M, Breckenridge A. Induction of drug metabolizing enzymes in man. Clin Sci. 1970 Sep;39(3):11P. PubMed PMID: 5459153.
  368. Breckenridge A, Dollery CT, Parry EH. Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967. Q J Med. 1970 Jul;39(155):411-29. PubMed PMID: 5478509.
  369. Sellwood RA, Wapnick S, Breckenridge A, Williams ED, Welbourn RB. Recurrent phaeochromocytoma. Br J Surg. 1970 Apr;57(4):309-12. PubMed PMID: 5437931.
  370. Breckenridge A, Orme ML, Davies DS, Thorgeirsson S. Induction of drug metabolizing enzymes in man and rat by dichloralphenazone. Clin Sci. 1969 Oct;37(2):565. PubMed PMID: 5359008.
  371. Breckenridge A, Davies DS, Orme ML, Thorgeirsson S. Screening methods for measuring liver microsomal enzyme induction by drugs. J Physiol. 1969 May;202(1):15P-16P. PubMed PMID: 5770876.
  372. Breckenridge A, Dollery CT. Changing pattern of death in hypertension. Br Heart J. 1969 May;31(3):387. PubMed PMID: 5401819.
  373. Sherwood T, Doyle FH, Breckenridge A, Dollery CT, Steiner RE. Value of fluid deprivation in large-dose urography. Lancet. 1968 Oct 5;2(7571):754-5. PubMed PMID: 4175552.
  374. Sherwood T, Breckenridge A, Dollery CT, Doyle FH, Steiner RE. Intravenous urography and renal function. Clin Radiol. 1968 Jul;19(3):296-302. PubMed PMID: 5677646.
  375. Breckenridge A, Dollery CT, Worlledge SM, Holborow EJ, Johnson GD. Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet. 1967 Dec 16;2(7529):1265-7. PubMed PMID: 4168609.
  376. Doyle FH, Sherwood T, Steiner RE, Breckenridge A, Dollery CT. Large-dose urography. Is there an optimum dose? Lancet. 1967 Nov 4;2(7523):964-6. PubMed PMID: 4167519.
  377. Breckenridge A, Preger L, Dollery CT, Laws JW. Hypertension in the young. Q J Med. 1967 Oct;36(144):549-63. PubMed PMID: 6077231.
  378. Sherwood T, Dollery CT, Breckenridge A. What is the nephrogram? Lancet. 1967 Apr 8;1(7493):784. PubMed PMID: 4164134.
  379. Breckenridge A, Welborn TA, Dollery CT, Fraser R. Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet. 1967 Jan 14;1(7481):61-4. PubMed PMID: 4163120.
  380. Carstairs KC, Breckenridge A, Dollery CT, Worlledge SM. Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet. 1966 Jul 16;2(7455):133-5. PubMed PMID: 4161378.
  381. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet. 1966 Jun 18;1(7451):1336-7. PubMed PMID: 4160743.
  382. Breckenridge A, Dollery CT. Combined action of methyldopa and bethanidine. Evidence for a synergistic effect. Lancet. 1966 May 14;1(7446):1074-6. PubMed PMID: 4160847.
  383. Breckenridge A. Angiotensin infusion test in hypertension. Am Heart J. 1966 May;71(5):714-5. PubMed PMID: 4286962.
  384. Breckenridge A. Hypertension and hyperuricaemia. Proc R Soc Med. 1966 Apr;59(4):316-9. PubMed PMID: 5937680; PubMed Central PMCID: PMC1900599.
  385. Carstairs K, Worlledge S, Dollery CT, Breckenridge A. Methyldopa and haemolytic anaemia. Lancet. 1966 Jan 22;1(7430):201. PubMed PMID: 4159012.
  386. Breckenridge A. Hypertension and hyperuricaemia. Lancet. 1966 Jan 1;1(7427):15-8. PubMed PMID: 4159153.
  387. BRECKENRIDGE A, METCALFE-GIBSON A. METHODS OF MEASURING GLOMERULAR-FILTRATION RATE: A COMPARISON OF INULIN, VITAMIN-B 12 AND CREATININE CLEARANCES. Lancet. 1965 Aug 7;2(7406):265-7. PubMed PMID: 14330062.
  388. BRECKENRIDGE A. ANGIOTENSIN-INFUSION TEST. Lancet. 1965 Jul 31;1(7405):209-11. PubMed PMID: 14315229.
  389. WATSON H, BRECKENRIDGE AM, LOWE KG. RIGHT VENTRICULAR PRESSURE FLOW RELATIONSHIPS AND INTRACARDIAC VENTURI EFFECTS IN FALLOT’S TETRALOGY. Br Heart J. 1964 Nov;26:794-805. PubMed PMID: 14222549; PubMed Central PMCID: PMC1018132.

download complete list of publications

[/wm_item][/wm_tabs][/vc_column][/vc_row]